Mediwound (MDWD) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
MediWound Ltd. has reported a robust second quarter in 2024 with the completion of a new NexoBrid manufacturing facility and a strategic $25 million investment from Mölnlycke Health Care. The company has also secured €16.25 million in European Innovation Council funding to accelerate the development of EscharEx for diabetic foot ulcers, with anticipated revenue growth. These developments, along with the initiation of a Phase III study for venous leg ulcers, signify MediWound’s strong position in the enzymatic therapeutics market for tissue repair.
For further insights into MDWD stock, check out TipRanks’ Stock Analysis page.
